Also, it is presently not clear to what extent our findings regarding the antifibrotic roles of cGKI in Postn+ CMF apply to post-MI hearts or to HF with preserved EF (HFpEF), which is a heterogeneous syndrome and proved to be a difficult entity to treat with many well-established HFrEF medications [100,101]. The gene discussed is PRKG1; the disease is hydrops fetalis.